242 related articles for article (PubMed ID: 31648405)
1. Retrospective comparison of first-line adjuvant anthracycline vs metronomic-based chemotherapy protocols in the treatment of stage I and II canine splenic haemangiosarcoma.
Treggiari E; Borrego JF; Gramer I; Valenti P; Harper A; Finotello R; Toni C; Laomedonte P; Romanelli G
Vet Comp Oncol; 2020 Mar; 18(1):43-51. PubMed ID: 31648405
[TBL] [Abstract][Full Text] [Related]
2. Adjuvant anthracycline-based vs metronomic chemotherapy vs no medical treatment for dogs with metastatic splenic hemangiosarcoma: A multi-institutional retrospective study of the Italian Society of Veterinary Oncology.
Marconato L; Chalfon C; Finotello R; Polton G; Vasconi ME; Annoni M; Stefanello D; Mesto P; Capitani O; Agnoli C; Amati M; Sabattini S
Vet Comp Oncol; 2019 Dec; 17(4):537-544. PubMed ID: 31251441
[TBL] [Abstract][Full Text] [Related]
3. The addition of metronomic chemotherapy does not improve outcome for canine splenic haemangiosarcoma.
Alexander CK; Cronin KL; Silver M; Gardner HL; London C
J Small Anim Pract; 2019 Jan; 60(1):32-37. PubMed ID: 30209807
[TBL] [Abstract][Full Text] [Related]
4. A retrospective analysis of chemotherapy switch suggests improved outcome in surgically removed, biologically aggressive canine haemangiosarcoma.
Finotello R; Henriques J; Sabattini S; Stefanello D; Felisberto R; Pizzoni S; Ferrari R; Marconato L
Vet Comp Oncol; 2017 Jun; 15(2):493-503. PubMed ID: 26792231
[TBL] [Abstract][Full Text] [Related]
5. Impact of repeated cycles of EGF bispecific angiotoxin (eBAT) administered at a reduced interval from doxorubicin chemotherapy in dogs with splenic haemangiosarcoma.
Borgatti A; Fieberg A; Winter AL; Stuebner K; Taras E; Todhunter D; Masyr A; Rendhal A; Vallera DA; Koopmeiners JS; Modiano JF
Vet Comp Oncol; 2020 Dec; 18(4):664-674. PubMed ID: 32187827
[TBL] [Abstract][Full Text] [Related]
6. Survival time of dogs with splenic hemangiosarcoma treated by splenectomy with or without adjuvant chemotherapy: 208 cases (2001-2012).
Wendelburg KM; Price LL; Burgess KE; Lyons JA; Lew FH; Berg J
J Am Vet Med Assoc; 2015 Aug; 247(4):393-403. PubMed ID: 26225611
[TBL] [Abstract][Full Text] [Related]
7. Adjuvant Doxorubicin with or without Metronomic Cyclophosphamide for Canine Splenic Hemangiosarcoma.
Matsuyama A; Poirier VJ; Mantovani F; Foster RA; Mutsaers AJ
J Am Anim Hosp Assoc; 2017; 53(6):304-312. PubMed ID: 28892429
[TBL] [Abstract][Full Text] [Related]
8. Does thalidomide prolong survival in dogs with splenic haemangiosarcoma?
Bray JP; Orbell G; Cave N; Munday JS
J Small Anim Pract; 2018 Feb; 59(2):85-91. PubMed ID: 29210452
[TBL] [Abstract][Full Text] [Related]
9. Timely adjuvant chemotherapy improves outcome in dogs with non-metastatic splenic hemangiosarcoma undergoing splenectomy.
Faroni E; Sabattini S; Guerra D; Iannuzzi C; Chalfon C; Agnoli C; Stefanello D; Polton G; Ramos S; Aralla M; Ciaccini R; Foglia A; Okonji S; Marconato L
Vet Comp Oncol; 2023 Mar; 21(1):123-130. PubMed ID: 36633399
[TBL] [Abstract][Full Text] [Related]
10. Epirubicin in the adjuvant treatment of splenic hemangiosarcoma in dogs: 59 cases (1997-2004).
Kim SE; Liptak JM; Gall TT; Monteith GJ; Woods JP
J Am Vet Med Assoc; 2007 Nov; 231(10):1550-7. PubMed ID: 18021000
[TBL] [Abstract][Full Text] [Related]
11. Maintenance therapy with toceranib following doxorubicin-based chemotherapy for canine splenic hemangiosarcoma.
Gardner HL; London CA; Portela RA; Nguyen S; Rosenberg MP; Klein MK; Clifford C; Thamm DH; Vail DM; Bergman P; Crawford-Jakubiak M; Henry C; Locke J; Garrett LD
BMC Vet Res; 2015 Jun; 11():131. PubMed ID: 26062540
[TBL] [Abstract][Full Text] [Related]
12. Evaluation of clinical and histologic factors associated with survival time in dogs with stage II splenic hemangiosarcoma treated by splenectomy and adjuvant chemotherapy: 30 cases (2011-2014).
Moore AS; Rassnick KM; Frimberger AE
J Am Vet Med Assoc; 2017 Sep; 251(5):559-565. PubMed ID: 28828962
[TBL] [Abstract][Full Text] [Related]
13. Continuous low-dose oral chemotherapy for adjuvant therapy of splenic hemangiosarcoma in dogs.
Lana S; U'ren L; Plaza S; Elmslie R; Gustafson D; Morley P; Dow S
J Vet Intern Med; 2007; 21(4):764-9. PubMed ID: 17708397
[TBL] [Abstract][Full Text] [Related]
14. VAC protocol for treatment of dogs with stage III hemangiosarcoma.
Alvarez FJ; Hosoya K; Lara-Garcia A; Kisseberth W; Couto G
J Am Anim Hosp Assoc; 2013; 49(6):370-7. PubMed ID: 24051260
[TBL] [Abstract][Full Text] [Related]
15. Doxorubicin and deracoxib adjuvant therapy for canine splenic hemangiosarcoma: a pilot study.
Kahn SA; Mullin CM; de Lorimier LP; Burgess KE; Risbon RE; Fred RM; Drobatz K; Clifford CA
Can Vet J; 2013 Mar; 54(3):237-42. PubMed ID: 23997259
[TBL] [Abstract][Full Text] [Related]
16. Comparison of doxorubicin-cyclophosphamide with doxorubicin-dacarbazine for the adjuvant treatment of canine hemangiosarcoma.
Finotello R; Stefanello D; Zini E; Marconato L
Vet Comp Oncol; 2017 Mar; 15(1):25-35. PubMed ID: 25623994
[TBL] [Abstract][Full Text] [Related]
17. Canine visceral hemangiosarcoma treated with surgery alone or surgery and doxorubicin: 37 cases (2005-2014).
Batschinski K; Nobre A; Vargas-Mendez E; Tedardi MV; Cirillo J; Cestari G; Ubukata R; Dagli MLZ
Can Vet J; 2018 Sep; 59(9):967-972. PubMed ID: 30197439
[TBL] [Abstract][Full Text] [Related]
18. Evaluation of an autologous cancer vaccine for the treatment of metastatic canine hemangiosarcoma: a preliminary study.
Lucroy MD; Clauson RM; Suckow MA; El-Tayyeb F; Kalinauskas A
BMC Vet Res; 2020 Nov; 16(1):447. PubMed ID: 33208160
[TBL] [Abstract][Full Text] [Related]
19. Efficacy of doxorubicin-based chemotherapy for non-resectable canine subcutaneous haemangiosarcoma.
Wiley JL; Rook KA; Clifford CA; Gregor TP; Sorenmo KU
Vet Comp Oncol; 2010 Sep; 8(3):221-33. PubMed ID: 20691029
[TBL] [Abstract][Full Text] [Related]
20. Evaluation of a novel tumor vaccine in dogs with hemangiosarcoma.
U'Ren LW; Biller BJ; Elmslie RE; Thamm DH; Dow SW
J Vet Intern Med; 2007; 21(1):113-20. PubMed ID: 17338158
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]